CN106132963B - (5,6-二氢)嘧啶并[4,5-e]吲嗪 - Google Patents

(5,6-二氢)嘧啶并[4,5-e]吲嗪 Download PDF

Info

Publication number
CN106132963B
CN106132963B CN201580017365.8A CN201580017365A CN106132963B CN 106132963 B CN106132963 B CN 106132963B CN 201580017365 A CN201580017365 A CN 201580017365A CN 106132963 B CN106132963 B CN 106132963B
Authority
CN
China
Prior art keywords
indolizine
carboxamide
anilino
dihydropyrimido
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580017365.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106132963A (zh
Inventor
A·P·A·德曼
R·C·比杰斯曼
J·G·斯特恩伯格
J·C·M·乌特德哈格
J·J·P·德维特
G·J·R·扎曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SILLAJEN Inc
Original Assignee
Netherlands Translational Research Center BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Research Center BV filed Critical Netherlands Translational Research Center BV
Publication of CN106132963A publication Critical patent/CN106132963A/zh
Application granted granted Critical
Publication of CN106132963B publication Critical patent/CN106132963B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580017365.8A 2014-04-07 2015-03-30 (5,6-二氢)嘧啶并[4,5-e]吲嗪 Active CN106132963B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (2)

Publication Number Publication Date
CN106132963A CN106132963A (zh) 2016-11-16
CN106132963B true CN106132963B (zh) 2019-08-06

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580017365.8A Active CN106132963B (zh) 2014-04-07 2015-03-30 (5,6-二氢)嘧啶并[4,5-e]吲嗪

Country Status (16)

Country Link
US (3) USRE48974E1 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368767B (es) * 2014-04-07 2019-10-15 Netherlands Translational Res Center B V (5,6-dihidro)pirimido[4,5-e]indolizinas.
JP6993233B2 (ja) * 2015-04-17 2022-01-13 ネザーランズ トランスレーショナル リサーチ センター ビー．ブイ． Ｔｔｋ阻害剤化学療法の為の予後バイオマーカー
PL3416964T3 (pl) * 2016-02-19 2021-10-18 Phoenix Molecular Designs Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego
HUE057838T2 (hu) 2016-06-07 2022-06-28 Jacobio Pharmaceuticals Co Ltd SHP2 inhibitorokként hasznos új heterociklusos származékok
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
US20250049926A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical compositions comprising modified betacyclodextrins
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
KR20240107329A (ko) * 2021-12-15 2024-07-09 신라젠(주) 신생물성 질환을 치료하는 방법
KR20240144991A (ko) * 2022-03-04 2024-10-04 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
KR101084871B1 (ko) 2003-05-22 2011-11-21 네르비아노 메디칼 사이언시스 에스.알.엘. 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
ES2553114T3 (es) 2009-07-29 2015-12-04 Nerviano Medical Sciences S.R.L. Sales de inhibidor de plk
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
ES2657979T3 (es) 2013-06-24 2018-03-07 Merck Patent Gmbh Compuestos de imidazol como moduladores de FSHR y sus usos
MX368767B (es) * 2014-04-07 2019-10-15 Netherlands Translational Res Center B V (5,6-dihidro)pirimido[4,5-e]indolizinas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity";Joost C.M. Uitdehaag et al.;《Journal of Molecular Biology》;20170521;第429卷;第2211-2230页 *

Also Published As

Publication number Publication date
JP6518690B2 (ja) 2019-05-22
USRE50082E1 (en) 2024-08-20
JP2017510595A (ja) 2017-04-13
EP3129374A1 (en) 2017-02-15
US9856258B2 (en) 2018-01-02
BR112016022342A8 (pt) 2021-07-20
USRE48974E1 (en) 2022-03-15
CA2944610C (en) 2024-01-09
KR20170013866A (ko) 2017-02-07
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
AU2015243694B2 (en) 2019-01-17
EP3129374B1 (en) 2018-12-19
RU2016141405A3 (enExample) 2018-10-02
CN106132963A (zh) 2016-11-16
ES2716165T3 (es) 2019-06-10
BR112016022342B1 (pt) 2022-10-04
MX2016012997A (es) 2016-12-07
RU2016141405A (ru) 2018-05-07
MX368767B (es) 2019-10-15
CA2944610A1 (en) 2015-10-15
KR102432420B1 (ko) 2022-08-17
DK3129374T3 (en) 2019-04-08
AU2015243694A1 (en) 2016-11-03
PL3129374T3 (pl) 2019-07-31
PT3129374T (pt) 2019-03-25
BR112016022342A2 (pt) 2017-08-15
HUE043108T2 (hu) 2019-07-29
RU2692479C2 (ru) 2019-06-25

Similar Documents

Publication Publication Date Title
CN106132963B (zh) (5,6-二氢)嘧啶并[4,5-e]吲嗪
CN106660993B (zh) 一类激酶抑制剂
CN104854101B (zh) Alk激酶抑制剂
US9890168B2 (en) 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CN113166110B (zh) 2-氨基嘧啶类化合物及其应用
WO2020200158A1 (zh) 用于治疗癌症的氮杂芳环酰胺衍生物
TW201219383A (en) Chemical compounds
CN106170288A (zh) 药物化合物
WO2005063709A1 (ja) アミド誘導体及び医薬
CN112574255A (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
CN101981032A (zh) 用于治疗由GSK3-β的异常活性引起的神经变性疾病的取代的芳基酰胺二氮杂并嘧啶酮衍生物
JP6257835B2 (ja) 新規なトリアゾロピリミジノン又はトリアゾロピリジノン誘導体、及びこれらの用途
WO2022188819A1 (zh) Sos1蛋白水解调节剂及其制备方法和应用
AU2014351413A1 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN112313207A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
WO2024175065A1 (zh) 一类含有芳基取代的cdk12/13的降解剂，及其制备方法、药物组合物和应用
HK1231072B (zh) (5，6-二氢)嘧啶并[4，5-e]吲嗪
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK40079587B (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
HK1198164B (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
HK1198164A1 (zh) 3，5-双取代炔基苯化合物及其盐

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231072

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250901

Address after: Republic of Korea

Patentee after: SILLAJEN, Inc.

Country or region after: Republic of Korea

Address before: Os, Netherlands

Patentee before: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.

Country or region before: Netherlands